Therefore, it is possible that low levels of sfrp gene promoter methylation or the relatively low serum SFRP5 levels observed in HBV-associated chronic hepatitis and liver cirrhosis may serve as biomarker for the risk of developing HCC. The gene discussed is SFRP5; the disease is cirrhosis of liver.